Does C-reactive protein predict time to recovery and benefit from oseltamivir treatment in primary care patients with influenza-like illness? A randomized controlled trial secondary analysis.
Saved in:
| Title: | Does C-reactive protein predict time to recovery and benefit from oseltamivir treatment in primary care patients with influenza-like illness? A randomized controlled trial secondary analysis. |
|---|---|
| Authors: | Harbin, Nicolay Jonassen (AUTHOR), Rystedt, Karin (AUTHOR), Lindbaek, Morten (AUTHOR), Radzeviciene, Ruta (AUTHOR), Westin, Johan (AUTHOR), Gunnarsson, Ronny (AUTHOR), Butler, Christopher C. (AUTHOR), van der Velden, Alike W. (AUTHOR), Verheij, Theo J. (AUTHOR), Sundvall, Pär-Daniel (AUTHOR) |
| Source: | Scandinavian Journal of Primary Health Care. Dec 2021, Vol. 39 Issue 4, p527-532. 6p. |
| Subjects: | C-reactive protein, Confidence intervals, Convalescence, Time, Primary health care, Treatment effectiveness, Influenza, Descriptive statistics, Kaplan-Meier estimator, Data analysis software, Oseltamivir, Secondary analysis |
| Abstract: | Recovery time and treatment effect of oseltamivir in influenza-like illness (ILI) differs between patient groups. A point-of-care test to better predict ILI duration and identify patients who are most likely to benefit from oseltamivir treatment would aid prescribing decisions in primary care. This study aimed to investigate whether a C-reactive protein (CRP) concentration of ≥30 mg/L can predict (1) ILI disease duration, and (2) which patients are most likely to benefit from oseltamivir treatment. Secondary analysis of randomized controlled trial data. Primary care in Lithuania, Sweden and Norway during three consecutive influenza seasons 2016–2018. A total of 277 ILI patients aged one year or older and symptom duration of ≤72 h. Capillary blood CRP concentration at baseline, and ILI recovery time defined as having 'returned to usual daily activity' with residual symptoms minimally interfering. At baseline, 20% (55/277) had CRP concentrations ≥30mg/L (range 0–210). CRP concentration ≥30 mg/L was not associated with recovery time (adjusted hazards ratio (HR) 0.80: 95% CI 0.50–1.3; p = 0.33). Interaction analysis of CRP concentration ≥30 mg/L and oseltamivir treatment did not identify which patients benefit more from oseltamivir treatment (adjusted HR 0.69: 95% CI 0.37–1.3; p = 0.23). There was no association between CRP concentration of ≥30 mg/L and recovery time from ILI. Furthermore, CRP could not predict which ILI patients benefit more from oseltamivir treatment. Hence, we do not recommend CRP testing for predicting ILI recovery time or identifying patients who will receive particular benefit from oseltamivir treatment. Predicting disease course of influenza-like illness (ILI), and identifying which patients benefit from oseltamivir treatment is a challenge for physicians. • There was no association between CRP concentration at baseline and recovery time in patients consulting with ILI in primary care. • There was no association between CRP concentration at baseline and benefit from oseltamivir treatment. • We, therefore, do not recommend CRP testing for predicting recovery time or in decision-making concerning oseltamivir prescribing in ILI patients. [ABSTRACT FROM AUTHOR] |
| Copyright of Scandinavian Journal of Primary Health Care is the property of Taylor & Francis Ltd and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) | |
| Database: | Psychology and Behavioral Sciences Collection |
| FullText | Links: – Type: pdflink Text: Availability: 0 |
|---|---|
| Header | DbId: pbh DbLabel: Psychology and Behavioral Sciences Collection An: 154318865 AccessLevel: 6 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Does C-reactive protein predict time to recovery and benefit from oseltamivir treatment in primary care patients with influenza-like illness? A randomized controlled trial secondary analysis. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AR" term="%22Harbin%2C+Nicolay+Jonassen%22">Harbin, Nicolay Jonassen</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Rystedt%2C+Karin%22">Rystedt, Karin</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Lindbaek%2C+Morten%22">Lindbaek, Morten</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Radzeviciene%2C+Ruta%22">Radzeviciene, Ruta</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Westin%2C+Johan%22">Westin, Johan</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Gunnarsson%2C+Ronny%22">Gunnarsson, Ronny</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Butler%2C+Christopher+C%2E%22">Butler, Christopher C.</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22van+der+Velden%2C+Alike+W%2E%22">van der Velden, Alike W.</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Verheij%2C+Theo+J%2E%22">Verheij, Theo J.</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Sundvall%2C+Pär-Daniel%22">Sundvall, Pär-Daniel</searchLink> (AUTHOR) – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22Scandinavian+Journal+of+Primary+Health+Care%22">Scandinavian Journal of Primary Health Care</searchLink>. Dec 2021, Vol. 39 Issue 4, p527-532. 6p. – Name: Subject Label: Subjects Group: Su Data: <searchLink fieldCode="DE" term="%22C-reactive+protein%22">C-reactive protein</searchLink><br /><searchLink fieldCode="DE" term="%22Confidence+intervals%22">Confidence intervals</searchLink><br /><searchLink fieldCode="DE" term="%22Convalescence%22">Convalescence</searchLink><br /><searchLink fieldCode="DE" term="%22Time%22">Time</searchLink><br /><searchLink fieldCode="DE" term="%22Primary+health+care%22">Primary health care</searchLink><br /><searchLink fieldCode="DE" term="%22Treatment+effectiveness%22">Treatment effectiveness</searchLink><br /><searchLink fieldCode="DE" term="%22Influenza%22">Influenza</searchLink><br /><searchLink fieldCode="DE" term="%22Descriptive+statistics%22">Descriptive statistics</searchLink><br /><searchLink fieldCode="DE" term="%22Kaplan-Meier+estimator%22">Kaplan-Meier estimator</searchLink><br /><searchLink fieldCode="DE" term="%22Data+analysis+software%22">Data analysis software</searchLink><br /><searchLink fieldCode="DE" term="%22Oseltamivir%22">Oseltamivir</searchLink><br /><searchLink fieldCode="DE" term="%22Secondary+analysis%22">Secondary analysis</searchLink> – Name: Abstract Label: Abstract Group: Ab Data: Recovery time and treatment effect of oseltamivir in influenza-like illness (ILI) differs between patient groups. A point-of-care test to better predict ILI duration and identify patients who are most likely to benefit from oseltamivir treatment would aid prescribing decisions in primary care. This study aimed to investigate whether a C-reactive protein (CRP) concentration of ≥30 mg/L can predict (1) ILI disease duration, and (2) which patients are most likely to benefit from oseltamivir treatment. Secondary analysis of randomized controlled trial data. Primary care in Lithuania, Sweden and Norway during three consecutive influenza seasons 2016–2018. A total of 277 ILI patients aged one year or older and symptom duration of ≤72 h. Capillary blood CRP concentration at baseline, and ILI recovery time defined as having 'returned to usual daily activity' with residual symptoms minimally interfering. At baseline, 20% (55/277) had CRP concentrations ≥30mg/L (range 0–210). CRP concentration ≥30 mg/L was not associated with recovery time (adjusted hazards ratio (HR) 0.80: 95% CI 0.50–1.3; p = 0.33). Interaction analysis of CRP concentration ≥30 mg/L and oseltamivir treatment did not identify which patients benefit more from oseltamivir treatment (adjusted HR 0.69: 95% CI 0.37–1.3; p = 0.23). There was no association between CRP concentration of ≥30 mg/L and recovery time from ILI. Furthermore, CRP could not predict which ILI patients benefit more from oseltamivir treatment. Hence, we do not recommend CRP testing for predicting ILI recovery time or identifying patients who will receive particular benefit from oseltamivir treatment. Predicting disease course of influenza-like illness (ILI), and identifying which patients benefit from oseltamivir treatment is a challenge for physicians. • There was no association between CRP concentration at baseline and recovery time in patients consulting with ILI in primary care. • There was no association between CRP concentration at baseline and benefit from oseltamivir treatment. • We, therefore, do not recommend CRP testing for predicting recovery time or in decision-making concerning oseltamivir prescribing in ILI patients. [ABSTRACT FROM AUTHOR] – Name: AbstractSuppliedCopyright Label: Group: Ab Data: <i>Copyright of Scandinavian Journal of Primary Health Care is the property of Taylor & Francis Ltd and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.</i> (Copyright applies to all Abstracts.) |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=pbh&AN=154318865 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1080/02813432.2021.2006482 Languages: – Code: eng Text: English PhysicalDescription: Pagination: PageCount: 6 StartPage: 527 Subjects: – SubjectFull: C-reactive protein Type: general – SubjectFull: Confidence intervals Type: general – SubjectFull: Convalescence Type: general – SubjectFull: Time Type: general – SubjectFull: Primary health care Type: general – SubjectFull: Treatment effectiveness Type: general – SubjectFull: Influenza Type: general – SubjectFull: Descriptive statistics Type: general – SubjectFull: Kaplan-Meier estimator Type: general – SubjectFull: Data analysis software Type: general – SubjectFull: Oseltamivir Type: general – SubjectFull: Secondary analysis Type: general Titles: – TitleFull: Does C-reactive protein predict time to recovery and benefit from oseltamivir treatment in primary care patients with influenza-like illness? A randomized controlled trial secondary analysis. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Harbin, Nicolay Jonassen – PersonEntity: Name: NameFull: Rystedt, Karin – PersonEntity: Name: NameFull: Lindbaek, Morten – PersonEntity: Name: NameFull: Radzeviciene, Ruta – PersonEntity: Name: NameFull: Westin, Johan – PersonEntity: Name: NameFull: Gunnarsson, Ronny – PersonEntity: Name: NameFull: Butler, Christopher C. – PersonEntity: Name: NameFull: van der Velden, Alike W. – PersonEntity: Name: NameFull: Verheij, Theo J. – PersonEntity: Name: NameFull: Sundvall, Pär-Daniel IsPartOfRelationships: – BibEntity: Dates: – D: 01 M: 12 Text: Dec 2021 Type: published Y: 2021 Identifiers: – Type: issn-print Value: 02813432 Numbering: – Type: volume Value: 39 – Type: issue Value: 4 Titles: – TitleFull: Scandinavian Journal of Primary Health Care Type: main |
| ResultId | 1 |
